# Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.

> **NCT04299048** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 11 (actual)

## Conditions studied

- Cachexia
- Non-Small-Cell Lung Cancer
- Pancreatic Cancer
- Colorectal Cancer

## Interventions

- **DRUG:** PF-06946860

## Key facts

- **NCT ID:** NCT04299048
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-17
- **Primary completion:** 2022-03-30
- **Final completion:** 2022-03-30
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2023-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04299048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04299048, "Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04299048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*